Investment in MBLI Expands JSR Life Sciences
News Apr 22, 2016
Tim Lowery, Sr. Vice President of Emerging Technologies at JSR Micro, Inc., has been appointed as the Chief Executive Officer of MBLI effective immediately.
MBLI is a life sciences company focused on providing high quality, innovative, solutions-based products for life sciences research and clinical diagnostics. The company has more than 20 years of experience developing research products and technologies for immunology, cell biology and protein analysis as well as assays for disease biomarker analysis in immuno-oncology, cardiovascular disease, autoimmune disease and more. MBLI also provides diagnostic products for autoimmune disease, infectious disease and virology. MBLI integrates the operations of the Americas and European markets for the MBL group.
“Our investment in MBLI provides an important base for our future growth plans,” said Eric Johnson, President of JSR Micro, Inc. and Senior Executive Officer and General Manager Life Sciences Division of JSR Corporation. “We are committed to growing our life sciences business in the US and in advancing the success of MBLI.”
“I am excited to lead MBLI as we continue to expand our business in the US and European markets”, said Lowery. “MBLI has a long history and deep technology expertise in the life sciences research and diagnostics markets. We will continue to build on the company’s strengths and grow our business through internal research and key strategic partnerships.”
JSR Micro, Inc., as a US-based subsidiary of JSR Corporation, had been leading the business development of JSR Life Sciences in the North American market, and is now becoming the lead role for JSR’s global life sciences businesses. The acquisition of MBLI will let JSR Micro, Inc. and JSR Life Sciences reach into the diagnostics and research markets by further expanding its business and product portfolio, especially in North America and Europe. JSR Micro, Inc. plans to fully integrate its existing diagnostics and research products activities with those of MBLI and operate as a single unit.
Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.READ MORE